Summit Corporation PLC: Director/PDMR Shareholding | Company Announcements

Friday 30 October, 2009

Summit Corporation PLC

Director/PDMR Shareholding





Summit Corporation plc
("Summit" or "the Company")

DIRECTOR DEALINGS

Oxford, UK, 30 October 2009 -  Summit Corporation plc (AIM: SUMM) has
today been notified that Professor Stephen Davies, Non-executive
Director and co-founder of the Company, yesterday purchased 300,000
Ordinary shares of 1 pence each ("Ordinary Shares") at a price of
5.45 pence per share.

Professor Davies now holds a total of 6,508,748  shares representing
11.16 per percent of the issued share capital.

                              -- ENDS -

For more information, please contact:

Summit plc
Steven Lee, PhD
Richard Pye, PhD
Tel: +44 (0)1235 443939

Panmure Gordon
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc is a UK based drug discovery company with a major focus on
developing new therapeutics from its iminosugar drug discovery
platform.
Summit believes iminosugars are the key to gaining access to several
disease mechanisms where classical drug candidates have had little
success, and therefore offer a major opportunity for the discovery
and development of new medicines.
Carbohydrates play critical roles in maintaining correct function of
many normal processes in healthy individuals and provide a wealth of
new targets for drug discovery.  Iminosugars have the capability of
accessing such targets and offer the potential of generating new
medicines in a variety of major therapy areas.  Summit is currently
focussed on metabolic diseases, including diabetes, and anti-virals.
Commercially, Summit has a track record of signing programme
agreements and currently has an out-licensed product portfolio
comprising of seven drug programmes with BioMarin, Orient Pharma,
Evolva and the Lilly TB Drug Discovery Initiative.  In the future
these programmes may generate success based milestone payments and
royalties for Summit.
The company listed on the alternative investment market (AIM) of the
London Stock Exchange in October 2004 - symbol: SUMM.  Further
information about the company is available at www.summitplc.com.

---END OF MESSAGE---




This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.

Investegate takes no responsibility for the accuracy of the information within the site.

The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.